STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema-Reference-Cited by-同舟云学术

STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema

Published:2023-08-29 Issue:2 Volume:387 Page:214-225
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Bedian Vahe^ORCID,Biris Nikolaos^ORCID,Omer Charles,Chung Jou-Ku,Fuller James^ORCID,Dagher Rafif,Chandran Sachin,Harwin Peter,Kiselak Tomas,Violin Jonathan,Nichols Andrew,Bista Pradeep^ORCID

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference49 articles.

1. Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases;Abdel-Magid;ACS Med Chem Lett,2023

2. Real-space refinement in PHENIX for cryo-EM and crystallography;Afonine;Acta Crystallogr D Struct Biol,2018

3. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema;Aygören-Pürsün;N Engl J Med,2018

4. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis

5. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial;Banerji;JAMA,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration;Cell Biochemistry and Biophysics;2024-06

2. Hereditary angioedema: current therapeutic management and future approaches;Current Opinion in Allergy & Clinical Immunology;2024-05-13

3. The future of therapeutic options for hereditary angioedema;Annals of Allergy, Asthma & Immunology;2024-04

4. Unveiling Therapeutic Frontiers: DON/DRP-104 as Innovative Plasma Kallikrein Inhibitors Against Carcinoma-Associated Hereditary Angioedema Shocks - A Comprehensive Molecular Dynamics Exploration;2024-01-15

5. Hereditary Angioedema: Novel Molecules for Treatment of Acute Attacks and Long-Term Prophylaxis;Future Pharmacology;2024-01-12